+44 20 8123 2220
info@marketpublishers.com

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

https://marketpublishers.com/r/I4407893B58EN.html
Date: October 2018
Pages: 118
Price: US$ 3,500.00 (Single User License)
ID: I4407893B58EN

Abstracts

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

SUMMARY

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 39 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 3, 14 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report

covers products from therapy areas Oncology, Dermatology, Immunology and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Colon Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Alopecia, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Glioma, Gliosarcoma, Hematological Tumor, Hepatocellular Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ocular Melanoma, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under

development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

Identify the use of drugs for target identification and drug repurposing

+44 20 8123 2220
info@marketpublishers.com

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Systimmune Inc

Tempest Therapeutics Inc
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
(IO-102 + IO-103) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-0015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BEBT-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-5777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLH-1131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dCellVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-200271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-2455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linrodostat - Drug Profile
Product Description
Mechanism Of Action

R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3381916 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXD-26116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IDO1 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description

Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-8844 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: IO Biotech doses first patient in Phase I/II IO102 and Keytruda trial
Jul 31, 2018: Approval for clinical trial for class I new chemical drug—Anti-Tumor innovative drug (LY01013) in China
Jul 02, 2018: NewLink reports new Phase l positive data from trial for DIPG
Jun 20, 2018: NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131
Jun 04, 2018: NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018
May 16, 2018: NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
Apr 25, 2018: NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
Apr 25, 2018: Incyte to Present Data on Epacadostat at the 2018 ASCO Annual Meeting
Apr 15, 2018: NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary
Apr 06, 2018: NewLink Genetics Announces Review of Clinical Programs
Apr 06, 2018: Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3

+44 20 8123 2220
info@marketpublishers.com

Pivotal Trial of Indoximod Plus PD-1 Inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by BeiGene Ltd, H2 2018
Pipeline by BirchBioMed Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CanBas Co Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by IO Biotech ApS, H2 2018
Pipeline by iTeos Therapeutics SA, H2 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Pipeline by Luye Pharma Group Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Netherlands Translational Research Center BV, H2 2018
Pipeline by NewLink Genetics Corp, H2 2018
Pipeline by Phenex Pharmaceuticals AG, H2 2018
Pipeline by Regen BioPharma Inc, H2 2018

+44 20 8123 2220
info@marketpublishers.com

Pipeline by Systimmune Inc, H2 2018
Pipeline by Tempest Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Systimmune Inc
Tempest Therapeutics Inc

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

Product link: https://marketpublishers.com/r/I4407893B58EN.html

Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/I4407893B58EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com